EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)

被引：0
|
作者：
Helliwell, P. [1 ]
Van den Bosch, F. [2 ]
Coates, L. C. [3 ]
Gladman, D. D. [4 ]
Tasset, C. [5 ]
Meuleners, L. [5 ]
Gilles, L. [6 ]
Gheyle, L. [5 ]
Trivedi, M. [7 ]
Alani, M. [7 ,8 ]
Besuyen, R. [9 ]
Mease, P. J. [8 ,10 ]
机构：
[1] Univ Leeds, Leeds, W Yorkshire, England
[2] Ghent Univ Hosp, Ghent, Belgium
[3] Univ Oxford, Botnar Res Ctr, Oxford, England
[4] Univ Toronto, Toronto, ON, Canada
[5] Galapagos NV, Mechelen, Belgium
[6] LACO, Galapagos NV, Mechelen, Belgium
[7] Gilead Sci Inc, Foster City, CA USA
[8] Univ Washington, Seattle, WA 98195 USA
[9] Galapagos BV, Leiden, Netherlands
[10] Swedish Med Ctr, Seattle, WA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.2495
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0343
引用
收藏
页码：761 / 762
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
    Mease, Philip
    Helliwell, Philip
    Silwinska-Stanczyk, Paula
    Miakisz, Malgorzata
    Ostor, Andrew
    Peeva, Elena
    Vincent, Michael S.
    Sun, Qiankun
    Sikirica, Vanja
    Winnette, Randall
    Qiu, Ruolun
    Li, Gang
    Feng, Gang
    Beebe, Jean S.
    Martin, David A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 (08) : 1370 - 1380
  • [22] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: OPAL BEYOND, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
    Gladman, D. D.
    Rigby, W. F. C.
    Azevedo, V. F.
    Behrens, F.
    Blanco, R.
    Kaszuba, A.
    Kudlacz, E.
    Wang, C.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 135 - 136
  • [23] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, Atul
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth C.
    [J]. LANCET, 2018, 391 (10136): : 2213 - 2224
  • [24] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL
    Mease, P. J.
    Hall, S.
    FitzGerald, O.
    van der Heijde, D.
    Merola, J. F.
    Avila-Zapata, F.
    Cieslak, D.
    Graham, D.
    Wang, C.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 141 - 142
  • [25] Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    McInnes, Iain B.
    Kavanaugh, Arthur
    Gottlieb, Alice B.
    Puig, Lluis
    Rahman, Proton
    Ritchlin, Christopher
    Brodmerkel, Carrie
    Li, Shu
    Wang, Yuhua
    Mendelsohn, Alan M.
    Doyle, Mittie K.
    [J]. LANCET, 2013, 382 (9894): : 780 - 789
  • [26] Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
    Kavanaugh, Arthur
    van der Heijde, Desiree
    McInnes, Iain B.
    Mease, Philip
    Krueger, Gerald G.
    Gladman, Dafna D.
    Gomez-Reino, Juan
    Papp, Kim
    Baratelle, Anna
    Xu, Weichun
    Mudivarthy, Surekha
    Mack, Michael
    Rahman, Mahboob U.
    Xu, Zhenhua
    Zrubek, Julie
    Beutler, Anna
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (08): : 2504 - 2517
  • [27] Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled PSUMMIT 1 Trial
    Lunzer, R.
    [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2013, 20 (04): : 175 - 176
  • [28] A Randomized placebo-controlled study of INCB018424, a selective janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA)
    Williams, William
    Scherle, Peggy
    Shi, Jack
    Newton, Robert
    McKeever, Edward
    Fridman, Jordan
    Burn, Timothy
    Vaddi, Kris
    Levy, Richard
    Moreland, Larry
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S431 - S431
  • [29] EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
    Coates, Laura C.
    Mease, Philip J.
    Gladman, Dafna D.
    van den Bosch, Filip
    Tasset, Chantal
    Meuleners, Luc
    Besuyen, Robin
    Gao, Jingjing
    Trivedi, Mona
    Hendrikx, Thijs
    Helliwell, Philip
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1269 - 1270
  • [30] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
    Deodhar, Atul A.
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345